

AHA ICH Guidelines (2015)

- "Anticoagulation and antiplatelet therapy after non-lobar ICH might be considered" (IIb, B)
- "The usefulness of dabigatran, rivaroxaban, or apixaban in patients with atrial fibrillation and past ICH is uncertain" (IIb, C)
- "An important question to be addressed is the possible role of the newer direct OAC's in patients at increased ICH risk and the identification of the subgroup that might derive the greatest benefit from the tendency of these agents to trigger recurrent bleeding"

Yale school of medicine

OAT Resumption and Outcome

 Thrombosis and/or hemorrhagic events affect patients based on both long-term impact disability and mortality

> OVERALL STUDY GOAL (2) Focus on <u>functional status</u> as outcome of OAT resumption after ICH

- Primary outcome: Modified Rankin Scale (mRS): 0-3 at 1 year
- Additional outcomes of interest (at 1 year):
- Mortality
- Recurrent ICH
- · Ischemic Stroke

Yale school of medicine

SLIDE

C ()	-	
Study	Design a	nd Methods
Study	Dusigna	ind Methods

- Meta-analysis of individual-level data from three ICH studies:
 - 1. RETRACE study (multi-center), Germany (n = 542)
 - 2. MGH ICH study (single center), Boston USA (n = 268)
 - 3. ERICH study (multi-center), USA (n = 217)
- Inclusion Criteria:
 - 1. acute ICH (CT-confirmed)
 - 2. age 18 years or older
 - 3. history of non-valvular atrial fibrillation
 - 4. on OAT with VKA/NOAC
 - 5. no history of prior ICH (high re-bleeding risk)
- Statical methods:
 - Univariable and mulivariable analyses in each study
 - · Meta-analysis (random effects) to combine individual studies

Yale school of medicine

	RETR	RETRACE		MGH		ERICH	
	Lobar ICH	Non-lobar ICH	Lobar ICH	Non-lobar ICH	Lobar ICH	Non-loba ICH	
No. subjects	202	340	106	162	78	139	
Age (years)	74.7 (7.9)	74.6 (7.8)	73.4 (10.8)	70.2 (9.9)	73.8 (11.1)	71.3 (12.0	
Sex (male)	119 (59)	211 (62)	51 (48)	99 (61)	46 (59)	76 (55)	
ICH Volume		10.2 (4.8 - 22.0)	27.3 (11.0 - 57.4)	11.2 (4.6 - 21.9)	18.4 (6.2 - 43.7)	6.2 (1.6 - 15.8)	
OAT Resumption	38 (19)	72 (21) 🕇	38 (36)🕈	74 (46)	12 (15)	33 (24)	

tigingante? Ch


OAT Resumption and Outcomes						
Non-lobar ICH						
Effect of OAT Resumption						
Outcome at 1 Year	HR	95% CI	р			
Favorable Outcome (mRS 0 -3)	4.41	2.92-6.67	<0.0001			
Mortality	0.26	0.17-0.39	<0.0001			
All-cause Stroke	0.45	0.28-0.71	0.0008			
- Recurrent ICH	1.12	0.94-1.34	0.22			
- Ischemic Stroke	0.42	0.011				
	Lobar ICI	I				
Outcome at 1 Year Effect of OAT Resumption						
Outcome at 1 fear	HR	95% CI	р			
Favorable Outcome (mRS 0 -3)	4.15	2.81-6.13	<0.0001			
Mortality	0.29	0.20-0.42	<0.0001			
All-cause Stroke	0.51	0.32-0.80	0.004			
- Recurrent ICH	1.26	0.99-1.60	0.059			
- Ischemic Stroke	0.48	0.27-0.85	0.013			
Yale school of medicine			SLIDE			

OAT and Possible vs. Probable CAA								
Possible CAA (n=137)								
Outcome at 1 Year	Unadjusted			Adjusted				
	HR	95% CI	р	HR	95% CI	р		
Favorable Outcome (mRS 0 -3)	3.44	1.16-10.22	0.027	3.40	1.22-9.46	0.020		
Mortality	0.21	0.05-0.89	0.034	0.27	0.08-0.86	0.028		
Probable CAA (n=55)								
Outcome at 1 Year	Unadjusted			Adjusted				
	HR	95% CI	р	HR	95% CI	р		
Favorable Outcome (mRS 0 -3)	3.33	1.03-10.77	0.046	3.11	1.08-8.97	0.038		
Mortality	0.28	0.09-0.91	0.035	0.30	0.10-0.92	0.037		
Yale school of medi	CINE					SLIDE		

Conclusions

- OAT resumption after both lobar and non-lobar ICH
 - was associated with the following outcomes at 1 year:
 - Improved functional outcome
 - Decreased mortality risk
 - Decreased ischemic stroke risk
- OAT resumption after ICH due to possible / probable CAA
 was associated with decreased mortality and improved outcome
 Limitations:
 - Observational study framework
 - Follow-up limited to one year
 - Very few patients on NOAC
- Future Directions: findings support and offer design guidance for clinical trials of OAT resumption and outcome after ICH

Yale school of medicine



Objective

The primary aim of this trial will be to test the hypothesis that apixaban is superior to aspirin for reducing the rate of recurrent stroke (ischemic or hemorrhagic) or death.

The key secondary outcome of this trial will test the hypothesis that apixaban is superior to aspirin for improved functional outcome as measured by the modified Rankin Scale.

Yale school of medicine

Intervention					
Intervention: Randomized double blind RCT – Apixaban 5 mg po bid versus aspirin 81 mg po qd for one year post-randomization					
Yalc school of medicine	SLIDE 13				

Inclusion/Exclusion Criteria

Inclusion Criteria

- ICH, documented with CT or MRI
- ICH must have occurred in the 14-120 days months prior to randomization . Diagnosis of non-valvular AF, documented on electrocardiography or history

Exclusion Criteria

- Lobar ICH and \geq 5 lobar microhemorrhages
- Conditions other than AF for which the patient requires long term anti-coagulation (e.g., deep venous thrombosis)
- (e.g., deep version another sector). A different chinical indication for the use of an anti-platelet drug even if treated with apixaban, such as clopidogrel for recent coronary stenting Chronic kidney disease with serum creatinine $\geq 2.5 \text{ mg/dL}$.

Yale school of medicine

Miscellaneous

- A total of 700 subjects across 125 sites for 85% power to detect a hazard ratio of 0.6 •
- ASPIRE will be a 5 year study, with 3.5 years of enrollment and at least 1 year of follow up for all patients •
- We will collect and bank blood and imaging for ancillary and secondary analyses where possible
- We are participating in the international COCHROACH collaboration and organizing a pre-pooled patient level meta-analysis of global trials on this question •

Yale school of medicine

Steering Committee and Partners

- Steven Greenberg •
- Walter Kernan
- Jonathan Rosand
- David Tirschwell
- · Daniel Woo
- Study Statistician Jordan Elm
- NCC, DCC, Claudia Moy, Scott Janis
- · Medical Safety Monitor Alejandro Rabinstein
- · Chair, Adjudication Committee Wendy Ziai

Yale school of medicine